# Jie Wang

Source: https://onco.cc/people/wang-jie-cams/  
OnCo record `wang-jie-cams` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.

## Summary

Jie Wang is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. She led the RATIONALE-304 and RATIONALE-307 trials of tislelizumab, the PD-1 antibody from BeOne Medicines, formerly BeiGene, in non-small-cell lung cancer, and has been principal investigator on many other Chinese registrational lung cancer studies. These include EGFR tyrosine kinase inhibitor and ALK trials in non-small-cell lung cancer and studies of Chinese PD-1 antibodies in small-cell lung cancer. Her interests are lung cancer, immunotherapy, targeted therapy and clinical trials.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
- Specialisms: Lung cancer; Immunotherapy; Targeted therapy; Clinical trials

## Sources

- Cancer Hospital, CAMS: https://www.cicams.ac.cn
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20J%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20tislelizumab%20lung

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)
- institutions: [Cancer Hospital, Chinese Academy of Medical Sciences](https://onco.cc/institutions/cams-cancer-hospital/)

---
JSON: https://onco.cc/api/v1/entities/wang-jie-cams.json